The frequency of predicted MSH2/MLH1-mutant CRCs in the CRC population under study was observed at 17 percent (Supplementary Figure 1), similar to the reported prevalence of MSI in CRC [7]. This evidence concerns the gene MSH2 and colorectal carcinoma.